CRISPR-Cas Clinical Trial Update New clinical trials within gene editing are popping up all the time. Our latest clinical trials update includes 4 recently initiated trials, all using CRISPR-Cas technology to treat diseases including herpes simplex virus refractory keratitis, sickle cell disease, hereditary transthyretin amyloidosis or thalassemia genetic disease. In these trials, CRISPR-Cas is either used directly to treat the condition by editing an individual's genome in vivo or indirectly through ex vivo engineering of a cell-based therapy. |